D002318DisordersC141216050.648445Cardiovascular DiseasesFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation Resourcevivo:orcidIdORCID idPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonDivision of ResearchDepartment of Research and EvaluationKaiser Permanente Northern CaliforniaKaiser Permanente Southern CaliforniaAlanGoAlan S. Go, MD37.80931810000000-122.26769880000000148Go, Alan0000-0001-9109-0811Associate Director, Cardiovascular and Metabolic ConditionsCarlosIribarrenCarlos Iribarren, MD, MPH, PhD37.80931810000000-122.26769880000000159Iribarren, Carlos0000-0001-5622-1839Research Scientist IIIKristiReynoldsKristi L. Reynolds, PhD, MPH34.14383190000000-118.1409662000000072Reynolds, Kristi0000-0001-7619-1649Director, Division of Epidemiologic Research6.763820.0125124121research area of0.9918730.0112779583subject area forKaiser Permanente Northwest3Assistant Investigator / Research Scientist I1Senior Investigator / Research Scientist IIIStephenFortmannStephen P. Fortmann, MD45.55028160000000-122.6805230000000019Fortmann, Stephen0000-0002-1327-9341Interim Director Center for Health ResearchCenter for Health ResearchAnkeetBhattAnkeet Bhatt, MD284Bhatt, AnkeetResearch Scientist I37377609Fiorica PN, Sheng H, Zhu Q, Roh JM, Laurent CA, Ergas IJ, Delmerico J, Kwan ML, Kushi LH, Ambrosone CB, Yao SCancer research communicationsA Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study. Cancer Res Commun. 2023 06; 3(6):1104-1112.Cancer Res Commun2023-06-22T00:00:002023A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study.37381978Hovsepyan G, Barac A, Brasky TM, Shadyab AH, Lehman A, McLaughlin EM, Saquib N, Iyengar NM, Wild RA, Caan BJ, Desai P, Beebe Dimmer J, Thomson CA, Simon MSCancer medicinePre-diagnosis lipid levels and mortality after obesity-related cancer diagnosis in the Women's Health Initiative cardiovascular disease biomarker cohort. Cancer Med. 2023 08; 12(15):16626-16636.Cancer Med2023-06-29T00:00:002023Pre-diagnosis lipid levels and mortality after obesity-related cancer diagnosis in the Women's Health Initiative cardiovascular disease biomarker cohort.37014015Deo R, Dubin RF, Ren Y, Murthy AC, Wang J, Zheng H, Zheng Z, Feldman H, Shou H, Coresh J, Grams M, Surapaneni AL, Bhat Z, Cohen JB, Rahman M, He J, Saraf SL, Go AS, Kimmel PL, Vasan RS, Segal MR, Li H, Ganz PEuropean heart journalProteomic cardiovascular risk assessment in chronic kidney disease. Eur Heart J. 2023 06 20; 44(23):2095-2110.Eur Heart J2023-06-20T00:00:002023Proteomic cardiovascular risk assessment in chronic kidney disease.37231821An J, Zhou H, Ni L, Harrision TN, Wei R, Agiro A, Brahmbhatt YG, Oluwatosin Y, Schilling CG, Sim JJAmerican journal of nephrologyDiscontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes. Am J Nephrol. 2023; 54(7-8):258-267.Am J Nephrol2023-05-18T00:00:002023Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes.38271569Gold R, Cook N, Dankovchik J, Larson AE, Sheppler CR, Boston D, O'Connor PJ, McGrath BM, Stange KCThe American journal of managed careCardiovascular disease risk management during COVID-19: in-person vs virtual visits. Am J Manag Care. 2024 Jan 01; 30(1):e11-e18.Am J Manag Care2024-01-01T00:00:002024Cardiovascular disease risk management during COVID-19: in-person vs virtual visits.true1Interim Director Center for Health ResearchInterim Director Center for Health Researchtrue1Director, Division of Epidemiologic ResearchDirector, Division of Epidemiologic Researchtrue1Research Scientist IResearch Scientist Itrue1Associate Director, Cardiovascular and Metabolic ConditionsAssociate Director, Cardiovascular and Metabolic Conditionstrue1Research Scientist IIIResearch Scientist III